Health
2.1
Sanofi launches Phase 1/2 trials of mRNA acne vaccine in adults
Published 2 d ago1 sourceEvidence: Reported
Anadolu Agency ENFR
Sanofi is exploring an acquisition of US biotech Insmed, valued at over $26 billion, per Bloomberg sources. Deal would expand Sanofi's rare-disease portfolio but faces integration and pricing risks. Market impact hinges on deal terms and regulatory review.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Published 2 d ago1 sourceEvidence: Reported
Published 1 d ago4 sourcesEvidence: Reported
Published 15 h ago1 sourceEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 1 d ago2 sourcesEvidence: Unknown
Published 1 d ago2 sourcesEvidence: Reported
Published 1 d ago1 sourceEvidence: Reported
Published 1 d ago1 sourceEvidence: Reported